- |||||||||| Tracleer (bosentan) / J&J, Roche, Bridion (sugammadex) / Merck (MSD)
Considerations in the Management of a Down Syndrome Patient With Severe Pulmonary Hypertension Presenting With an Acute Abdomen (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_3042; Her medications include sildenafil, bosentan, treprostinil, levothyroxine, and ranitidine...You give two mg of Midazolam, 50 mg of Ketamine, 50 mcg of Fentanyl, 50 mg of Rocuronium, and start Propofol infusion at 200 mcg/kg/min...Why?-What would you do for pain control?-What would be your post-op disposition for this patient?Intraoperative continued: You decide to perform awake extubation, so you discontinue Propofol infusion and give Sugammadex for reversal...ABG shows pH 7.35, PaCO2 40, PaO2 85, BE -3, and lactate 2. You extubate the patient and transfer to CICU in stable condition.
- |||||||||| Tracleer (bosentan) / J&J, Roche, Bridion (sugammadex) / Merck (MSD)
Considerations in the Management of a Down Syndrome Patient With Severe Pulmonary Hypertension Presenting With an Acute Abdomen (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_128; Her medications include sildenafil, bosentan, treprostinil, levothyroxine, and ranitidine...You give two mg of Midazolam, 50 mg of Ketamine, 50 mcg of Fentanyl, 50 mg of Rocuronium, and start Propofol infusion at 200 mcg/kg/min...Why?-What would you do for pain control?-What would be your post-op disposition for this patient?Intraoperative continued: You decide to perform awake extubation, so you discontinue Propofol infusion and give Sugammadex for reversal...ABG shows pH 7.35, PaCO2 40, PaO2 85, BE -3, and lactate 2. You extubate the patient and transfer to CICU in stable condition.
- |||||||||| Tryvio (aprocitentan) / J&J
Journal: Aprocitentan (Tryvio) for hypertension. (Pubmed Central) - Jun 21, 2024 You extubate the patient and transfer to CICU in stable condition. No abstract available
- |||||||||| Retrospective data, Review, Journal: Pulmonary artery denervation versus conventional therapies for PAH: a systematic review and updated network meta-analysis. (Pubmed Central) - May 24, 2024
Compared with 16 types of conventional therapies and Placebo, PADN has advantage over nine single therapies and Placebo in improving 6MWD and appears to be better than two types of dual-drug combined therapies while with no statistical significance. PADN shows a favourable antihypertensive effect on mPAP and has a lower risk to trigger clinical worsening or hospitalization, while its risk on mortality and severe adverse events is still inconclusive.
- |||||||||| Tracleer (bosentan) / J&J, Roche
Pulmonary Hypertension in a Cystic Fibrosis Child Following COVID 19: Case Report (Exhibit Hall, Salon 9) - May 20, 2024 - Abstract #FOCIS2024FOCIS_448; Pulmonary arterial hypertension should be suspected in a CF patient presenting after COVID 19 with worsened respiratory status, unexplained desaturation, night sleep disturbances. The prevention of COVID 19 in CF cohort should be prioritized.
- |||||||||| Retrospective data, Review, Journal: Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis. (Pubmed Central) - Apr 23, 2024
Treatment for CTD-PAH had favorable effects on clinical and hemodynamic outcomes but not on survival and NT-proBNP levels. Different from the previous meta-analyses that focused on 6-MWD, time to clinical worsening, and CW as outcomes, this meta-analysis additionally reports the pooled analysis of change in FC, hemodynamic measurements (RAP, PVR, CI), and NT-proBNP, some of which have prognostic value for PAH.
- |||||||||| Tracleer (bosentan) / J&J, Roche
Generation and utilisation of an advanced iPSC-derived hepatocyte model for cholestasis modelling (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1939; DIC was induced with bosentan, a BSEP inhibitor, or by feeding excess chenodeoxycholic acid for 6 days... Our new iHEP model provides a more physiologically relevant platform for human cholestasis modelling, offering insights into disease mechanisms and facilitating screening of compounds that cause DIC.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Opsumit (macitentan) / Nippon Shinyaku, J&J, Tracleer (bosentan) / J&J, Roche
A PAH Drug Ranking Strategy for Individualized Combination Therapy Via Pulmonary Endoarterial Biopsy (San Diego Convention Center, Room 25A-C (Upper Level)) - Mar 17, 2024 - Abstract #ATS2024ATS_8762; This study demonstrates the utility of combining an endoarterial biopsy technique with genetic expression studies to generate a ranking system that can be used to select a potentially more effective drug or drug combination regimen for an individual patient at a certain a stage of PAH disease. Human studies will be necessary to demonstrate the utility of this approach.
- |||||||||| hydrocortisone / Generic mfg.
Effect of Hydrocortisone (HC) on Cardiac Mass in Preterm Intubated Infants < 30 weeks Gestational Age (Convention Center Exhibit Hall) - Mar 16, 2024 - Abstract #PAS2024PAS_4336; Spearman Background: Dexamethasone use in preterm infants has been associated with adverse effects including hypertension, and an increase in the left ventricular mass index (LVMI), a surrogate for left ventricular hypertrophy...None of the infants in the HC group were receiving sildenafil or bosentan at 36 weeks
- |||||||||| Tracleer (bosentan) / J&J, Roche, Rituxan (rituximab) / Roche
Anti-CD19 CAR-T cell therapy for refractory childhood-onset systemic lupus erythematosus () - Feb 25, 2024 - Abstract #LUPUS2024LUPUS_282; She was started on sildenafil and bosentan for PAH...Anti-CD19 CAR-T cell therapy was considered and performed after lymphodepletion with CYC (1500mg/m2) and fludarabine (90mg/m2)...Conclusions In this SLE patient with severe refractory disease, B-cell depletion and drug-free remission were rapidly achieved after anti-CD19 CAR-T cells infusion. Long-term efficacy assessment is needed.
- |||||||||| Tracleer (bosentan) / J&J, Roche, Zepzelca (lurbinectedin) / PharmaMar, Jazz
P1 data, PK/PD data, Journal, Metastases: Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study. (Pubmed Central) - Feb 24, 2024 No differences in terms of toxicity were found between LRB with and without BOS. In summary, the magnitude of the observed changes precludes a clinically relevant effect of BOS co-administration on LRB exposure and its safety profile.
- |||||||||| Opsumit (macitentan) / Nippon Shinyaku, J&J
EFFICACY AND SAFETY OF MACITENTAN IN REFRACTORY DIGITAL ULCERS (Poster Area) - Feb 13, 2024 - Abstract #SSWC2024SSWC_332; Most patients (90.9%) had received previously treatment with Bosentan, and the reason for withdrawal was inefficacy in 4 cases (40%) and adverse effects (liver toxicity) in 6 (60%). Our data show that Macitentan is an effective agent for ischemic digital refractory ulcers in patients suffering from SARDs with a favorable safety profile in clinical practice.
- |||||||||| Tracleer (bosentan) / J&J, Roche
BOSENTAN ACCELERATES DELAYED WOUND HEALING IN EPITHELIAL CELL-SPECIFIC FLI1 KNOCKOUT MICE BY RESTORING IMPAIRED REEPITHELIALIZATION (Poster Area) - Feb 13, 2024 - Abstract #SSWC2024SSWC_58; These results indicate that wound healing is delayed in Fli1 KcKO mice due to dysregulated reepithelialization and ECM remodeling, and that bosentan-dependent acceleration of Fli1-deficient keratinocyte migration contributes to the restoration of delayed wound healing in Fli1 KcKO mice. In human SSc, bosentan may act on keratinocytes and accelerate the healing of microtrauma, contributing to preventing the development of new digital ulcers.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Opsumit (macitentan) / Nippon Shinyaku, J&J, Tracleer (bosentan) / J&J, Roche
P4 data, Journal, Real-world evidence, Real-world: Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data. (Pubmed Central) - Jan 9, 2024 According to the results of the study, bosentan had the highest risk of liver injury and the combination regimens bosentan?+?sildenafil, bosentan?+?epoprostenol, and bosentan?+?iloprost had a stronger risk of liver injury. From the early stages of treatment, we need to regularly monitor the liver function of patients, especially for females and the elderly, and discontinue the suspected drug as soon as the liver injury occurs.
- |||||||||| Tracleer (bosentan) / J&J, Roche
Journal: Bosentan does not affect renal resistive index in scleroderma/systemic sclerosis patients. (Pubmed Central) - Dec 25, 2023 From the early stages of treatment, we need to regularly monitor the liver function of patients, especially for females and the elderly, and discontinue the suspected drug as soon as the liver injury occurs. In conclusion, in patients with SSc complicated by digital ulcers and normal to mildly diminished kidney function, bosentan had no effect on intrarenal hemodynamics, but reduced blood pressure levels and kidney function.
- |||||||||| Opsumit (macitentan) / Nippon Shinyaku, J&J, Tracleer (bosentan) / J&J, Roche
Journal, Real-world evidence, Claims database, Adherence, Real-world: Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study. (Pubmed Central) - Nov 22, 2023 Different background signals are observed for both fragmentation methods as well as unique fragments which opens the possibility of developing a selective quantitative assay with improved sample throughput, in particular for analytes present in different matrices. Real-world data for Japanese patients with PAH showed that persistence was significantly higher for macitentan, versus ambrisentan and bosentan, since its approval.
- |||||||||| Tracleer (bosentan) / J&J, Roche
Review, Journal: The Pathogenesis of Systemic Sclerosis: The Origin of Fibrosis and Interlink with Vasculopathy and Autoimmunity. (Pubmed Central) - Sep 28, 2023 Although vasculopathy is an important initial step of the pathogenesis for SSc, it is still unclear how vasculopathy is related to inflammation and fibrosis. In this review, we focused on the clinical evidence for vasculopathy, the major cellular players for the pathogenesis, including pericytes, adipocytes, endothelial cells (ECs), and myofibroblasts, and their signaling pathway to elucidate the relationship among vasculopathy, inflammation, and fibrosis in SSc.
- |||||||||| Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3585;
This is the first meta-analysis on CTD-PAH that reported the pooled analysis of change in functional class, hemodynamic measurements (RAP, PVR, CI), and NT-proBNP, some of which have important prognostic value for PAH. Improvement in exercise capacity and reduction in risk of CW in CTD-PAH patients were less pronounced compared to idiopathic PAH (IPAH).
|